🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,99 USD

Máx. histórico

178,74

2143 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,38%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+2,43%

Cierre anterior

18,54

Rango de hoy

18,52 – 19,26

Volumen hoy

1.328.200

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 23 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/01/2002 71,22 74,70 70,80 73,26 +1,75% 5,48% 50.517
15/01/2002 72,96 74,40 69,60 72,00 -0,58% 6,58% 49.400
14/01/2002 70,20 73,50 70,20 72,42 +2,03% 4,70% 29.283
11/01/2002 69,78 71,10 69,00 70,98 +1,55% 3,01% 19.983
10/01/2002 68,76 72,00 66,90 69,90 +2,19% 7,42% 51.717
09/01/2002 66,48 71,10 66,36 68,40 +1,79% 7,13% 45.800
08/01/2002 63,66 67,26 63,66 67,20 +4,48% 5,66% 18.750
07/01/2002 66,00 66,30 64,20 64,32 -2,46% 3,18% 23.967
04/01/2002 67,08 67,50 65,16 65,94 -2,05% 3,49% 26.050
03/01/2002 65,70 68,10 65,70 67,32 +1,63% 3,65% 39.217
02/01/2002 66,24 66,30 63,48 66,24 +1,19% 4,26% 26.050
31/12/2001 67,62 68,82 64,50 65,46 -2,50% 6,39% 42.350
28/12/2001 66,90 67,50 65,70 67,14 +0,45% 2,69% 20.467
27/12/2001 63,84 67,38 63,00 66,84 +4,60% 6,86% 44.883
26/12/2001 58,38 64,20 58,38 63,90 +7,58% 9,97% 37.550
24/12/2001 58,68 59,40 57,66 59,40 +1,75% 2,97% 8.533
21/12/2001 54,60 58,50 54,00 58,38 +7,63% 8,24% 26.033
20/12/2001 57,90 57,90 53,34 54,24 -4,24% 7,88% 18.550
19/12/2001 58,68 58,68 56,64 56,64 -3,77% 3,48% 25.350
18/12/2001 59,40 59,70 58,26 58,86 -1,41% 2,42% 19.500
17/12/2001 56,88 59,70 56,28 59,70 +4,96% 6,01% 24.400
14/12/2001 54,00 57,30 54,00 56,88 +4,75% 6,11% 43.183
13/12/2001 54,60 54,60 53,10 54,30 -1,09% 2,75% 14.400
12/12/2001 53,22 55,32 53,22 54,90 +5,17% 3,95% 30.300
11/12/2001 53,94 53,94 50,94 52,20 -1,81% 5,56% 14.750
10/12/2001 56,82 57,60 52,20 53,16 -8,66% 9,50% 18.167
07/12/2001 60,90 60,90 57,60 58,20 -5,55% 5,42% 47.267
06/12/2001 56,58 61,62 55,50 61,62 +8,68% 10,82% 43.733
05/12/2001 56,88 57,00 55,50 56,70 +0,00% 2,64% 19.767
04/12/2001 56,40 57,30 55,50 56,70 -0,21% 3,19% 16.583